Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

286317

Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma who have received three or more prior therapies, and who failed to respond to at least one immunomodulatory agent, one proteasome inhibitor, and one CD38 inhibitor. Xpovio also has won approval in Israel for the treatment of adults with diffuse large B-cell lymphoma (DLBCL) who received at least two prior lines of…

You must be logged in to read/download the full post.